Revance
美国
经典
行业类别
- 注射类产品 - 肉毒素
- 注射类产品：透明质酸填充剂
- 诊所管理 - 商业服务 - 软件系统 - 硬件设备 - 网页设计 - 网络服务
公司简介
Revance® is creating a new neuromodulator category, and true innovation in aesthetic medicine and therapeutic specialties with their lead investigational product candidate, DaxibotulinumtoxinA for Injection (DAXI).
In the Phase 3 SAKURA clinical trials, DAXI achieved unrivalled efficacy, including a median 24-week duration of effect in treating glabellar lines. Revance’s open-label, long-term safety study, SAKURA 3, was the largest clinical program of an aesthetic neuromodulator, and included nearly 2,700 patients and more than 3,800 treatments.
Revance anticipates commercial launch in 2020 upon FDA approval.
In the Phase 3 SAKURA clinical trials, DAXI achieved unrivalled efficacy, including a median 24-week duration of effect in treating glabellar lines. Revance’s open-label, long-term safety study, SAKURA 3, was the largest clinical program of an aesthetic neuromodulator, and included nearly 2,700 patients and more than 3,800 treatments.
Revance anticipates commercial launch in 2020 upon FDA approval.